Zinc protoporphyrin: A metabolite with a mission

Clinical Chemistry

Volumn 45, Issue 12, 1999, Pages 2060-2072

  Labbé, Robert F ^a   Vreman, Hendrik J ^b   Stevenson, David K ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTOPORPHYRIN ZINC;

BIOCHEMISTRY; BLOOD BANK; HEME SYNTHESIS; HUMAN; IRON DEFICIENCY; IRON METABOLISM; OBSTETRICS; PEDIATRICS; REVIEW;

EID: 0032710987     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.12.2060     Document Type: Review

References (130)

1. 1. Labbé RF. History and background of protoporphyrin testing. Clin Chem 1977;23:256-9.
2. 2. Labbe RF, Rettmer RL. Zinc protoporphyrin: a product of iron-deficient erythropoiesis. Semin Hematol 1989;26:40-6.
3. 3. National Committee on Clinical Laboratory Standards. Erythrocyte protoporphyrin testing: approved guideline. Villanova, PA: NCCLS, 1996.
4. 4. Grinstein M, Watson CJ. Studies of protoporphyrin III. Photoelectric and fluorophotometric methods for the quantitative determination of the protoporphyrin in blood. J Biol Chem 1943;147: 675-84.
5. 5. Dagg JH, Goldberg A, Lochhead A. Value of erythrocyte protoporphyrin in the diagnosis of latent iron deficiency (sideropenia). Br J Haematol 1966;12:326-30.
6. 6. Lamola AA, Yamane T. Zinc protoporphyrin in the erythrocytes of patients with lead intoxication and iron deficiency anemia. Science 1974;186:936-8.
7. 7. Labbe RF, Carlson TH. The physiological role of zinc protoporphyrin: an hypothesis. International Meeting on Porphyrin Metabolism and Iron Metabolism. Arnhem, The Netherlands: Netherlands J Med, 1993:A22-3.
8. 8. Marks GS, Nakatsu K, Brien JF. Does endogenous zinc protoporphyrin modulate carbon monoxide formation from heme? Implications for long-term potentiation, memory, and cognitive function. Can J Physiol Pharmacol 1993;71:753-4.
9. 9. Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. New York, NY: McGraw-Hill, 1989: 1305-65.
10. 10. Nuttall KL. Porphyrins and disorders of porphyrin metabolism. In: Burtis CA, Ashwood ER, eds. Tietz textbook of clinical chemistry, 3rd ed. Philadelphia: WB Saunders, 1999:1711-35.
11. 11. Bottomley SS, Muller-Eberhard U. Pathophysiology of heme synthesis. Semin Hematol 1988;25:282-302.
12. 12. Taketani S, Tokunaga R. Purification and substrate specificity of bovine liver-ferrochelatase. Eur J Biochem 1982;127:443-7.
13. 13. Bloomer JR, Reuter RJ, Morton KO, Wehner JM. Enzymatic formation of zinc-protoporphyrin by rat liver and its potential effect on hepatic heme metabolism. Gastroenterology 1983;85: 663-8.
14. 14. Labbe RF, Rettmer RL, Shah AG, Turnlund JR. Zinc protoporphyrin. Past, present, and future. Ann N Y Acad Sci 1987;514:7-14.
15. 15. Langer EE, Haining RG, Labbe RF, Jacobs P, Crosby EF, Finch CA. Erythrocyte protoporphyrin. Blood 1972;40:112-28.
16. 16. McLaren GD, Carpenter JT Jr, Nino HV. Erythrocyte protoporphyrin in the detection of iron deficiency. Clin Chem 1975;21:1121-7.
17. 17. Piomelli S, Lamola AA, Poh-Fitzpatrick MF, Seaman C, Harber LC. Erythropoietic protoporphyria and lead intoxication: the molecular basis for difference in cutaneous photosensitivity. I. Different rates of disappearance of protoporphyrin from the erythrocytes, both in vivo and in vitro. J Clin Investig 1975;56:1519-27.
18. 18. Maines MD. Zinc protoporphyrin is a selective inhibitor of heme oxygenase activity in the neonatal rat. Biochim Biophys Acta 1981;673:339-50.
19. 19. Vreman HJ, Ekstrand BC, Stevenson DK. Selection of metalloporphyrin heme oxygenase inhibitors based on potency and photoreactivity. Pediatr Res 1993;33:195-200.
20. 20. Qato MK, Maines MD. Prevention of neonatal hyperbilirubinemia in non-human primates by Zn-protoporphyrin. Biochem J 1985; 226:51-7.
21. 21. Vreman HJ, Gillman MJ, Stevenson DK. In vitro inhibition of adult rat intestinal heme oxygenase by metalloporphyrins. Pediatr Res 1989;26:362-5.
22. 22. Rodgers PA, Seidman DS, Wei PL, Dennery PA, Stevenson DK. Duration of action and tissue distribution of zinc protoporphyrin in neonatal rats. Pediatr Res 1996;39:1041-9.
23. 23. Maines MD, Mark JA, Ewing JF. Heme oxygenase: a likely regulator of cGMP production in the brain: induction in-vivo of HO-1 compensates for depression in NO synthase activity. Mol Cell Neurosci 1993;4:398-405.
24. 24. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997;37:517-54.
25. 25. Zhuo M, Small SA, Kandel ER, Hawkins RD. Nitric oxide and carbon monoxide produce activity-dependent long-term synaptic enhancement in hippocampus. Science 1993;260:1946-50.
26. 26. Maines MD. Heme oxygenase: clinical applications and functions. Boca Raton, FL: CRC Press, 1992:276pp.
27. 27. Mark JA, Maines MD. Tin-protoporphyrin-mediated disruption in vivo of heme oxygenase-2 protein integrity and activity in rat brain. Pediatr Res 1992;32:324-9.
28. 28. Lutton JD, Abraham NG, Drummond GS, Levere RD, Kappas A. Zinc porphyrins: potent inhibitors of hematopoiesis in animal and human bone marrow. Proc Natl Acad Sci U S A 1997;94: 1432-6.
29. 29. Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem 1969;244: 6388-94.
30. 30. Kutty RK, Maines MD. Purification and characterization of biliverdin reductase from rat liver. J Biol Chem 1981;256:3956-62.
31. 31. Vreman HJ, Stevenson DK, Henton D, Rosenthal P. Correlation of carbon monoxide and bilirubin production by tissue homogenates. J Chromatogr 1988;427:315-9.
32. 32. Dennery PA, Rhine WD, Stevenson DK. Neonatal jaundice-what now? Clin Pediatr 1995;34:103-7.
33. 33. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci U S A 1987;84:5918-22.
34. 34. AAP. Practice parameter: management of hyperbilirubinemia in the healthy term newborn. American Academy of Pediatrics Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia [published erratum appears in Pediatrics 1995;95:458-61; see comments]. Pediatrics 1994;94: 558-65.
35. 35. Brown WR, Boon WH. Hyperbilirubinemia and kernicterus in glucose-6-phosphate dehydrogenase deficient infants in Singapore. Pediatrics 1968;41:1055-62.
36. 36. Crigler JFJ, Najjar VA. Congenital familial non-hemolytic jaundice with kernicterus. Pediatrics 1952;10:169-80.
37. 37. Slusher TM, Vreman HJ, McLaren DW, Lewison LJ, Brown AK, Stevenson DK. Glucose-6-phosphate dehydrogenase deficiency and carboxyhemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants. J Pediatr 1995; 126:102-8.
38. 38. Ennever JF. Blue light, green light, white light, more light: treatment of neonatal jaundice. Clin Perinatol 1990;17:467-81.
39. 39. Ostrow JD. Therapeutic amelioration of jaundice: old and new strategies. Hepatology 1988;8:683-9.
40. 40. Kappas A, Drummond GS. Control of heme metabolism with synthetic metalloporphyrins. J Clin Investig 1986;77:335-9.
41. 41. Stevenson DK, Rodgers PA, Vreman HJ. The use of metalloporphyrins for the chemoprevention of neonatal jaundice. Am J Dis Child 1989;143:353-6.
42. 42. Frydman RB, Tomaro ML, Buldain G, Awruch J, Díaz L, Frydman B. Specificity of heme oxygenase: a study with synthetic hemins. Biochemistry 1981;20:5177-82.
43. 43. Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 1988;2:2557-68.
44. 44. Maines M. Carbon monoxide and nitric oxide homology: differential modulation of heme oxygenases in brain and detection of protein and activity. Methods Enzymol 1996;268:473-88.
45. 45. Schacter BA. Heme catabolism by heme oxygenase: physiology, regulation, and mechanism of action. Semin Hematol 1988;25: 349-69.
46. 46. Berglund L, Angelin B, Hultcrantz R, Einarsson K, Emtestam L, Drummond G, Kappas A. Studies with the haeme oxygenase inhibitor Sn-protoporphyrin in patients with primary biliary cirrhosis and idiopathic haemochromatosis. Gut 1990;31:899-904.
47. 47. Galbraith RA, Drummond GS, Kappas A. Suppression of bilirubin production in the Crigler-Najjar type I syndrome: studies with the heme oxygenase inhibitor tin-mesoporphyrin [see comments]. Pediatrics 1992;89:175-82.
48. 48. Kappas A, Drummond GS, Manola T, Petmezaki S, Valaes T. Sn-protoporphyrin use in the management of hyperbilirubinemia in term newborns with direct Coombs-positive ABO incompatibility. Pediatrics 1988;81:485-97.
49. 49. Kappas A, Drummond GS, Henschke C, Valaes T. Direct comparison of Sn-mesoporphyrin, an inhibitor of bilirubin production, and phototherapy in controlling hyperbilirubinemia in term and near-term newborns. Pediatrics 1995;95:468-74.
50. 50. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci U S A 1968;61:748-55.
51. 51. Jones EA, Carson ER, Berk PD. The role of kinetic analysis and mathematical modeling in the study of bilirubin metabolism in vivo. In: Heirwegh KPM, Brown SB, eds. Bilirubin, Vol. II: Metabolism. Boca Raton, FL: CRC Press, 1982:133-72.
52. 52. Yao TC, Stevenson DK. Advances in the diagnosis and treatment of neonatal hyperbilirubinemia. Clin Perinatol 1995;22:741-58.
53. 53. Maisels MJ, Kring E. Transcutaneous bilirubinometry decreases the need for serum bilirubin measurements and saves money. Pediatrics 1997;99:599-601.
54. 54. Yamauchi Y, Yamanouchi I. Transcutaneous bilirubinometry: bilirubin kinetics of the skin and serum during and after phototherapy. Biol Neonate 1989;56:263-9.
55. 55. Vreman HJ, Verier J, Oh W, Fanaroff AA, Wright LL, Lemons JA, et al. Interlaboratory variability of bilirubin measurements [see comments]. Clin Chem 1996;42:869-73.
56. 56. Sjöstrand T. Endogenous formation of carbon monoxide in man under normal and pathological conditions. Scand J Clin Lab Investig 1949;1:201-14.
57. 57. Vreman HJ, Mahoney JJ, Stevenson DK. Carbon monoxide and carboxyhemoglobin. Adv Pediatr 1995;42:303-25.
58. 58. Goldsmith JR, Landaw SA. Carbon monoxide and human health. Science 1968;162:1352-9.
59. 59. Stevenson DK, Ostrander CR, Cohen RS, Johnson JD. Trace gas analysis in bilirubin metabolism: a technical review and current state of the art. Adv Pediatr 1982;29:129-49.
60. 60. Rodgers PA, Vreman HJ, Dennery PA, Stevenson DK. Sources of carbon monoxide (CO) in biological systems and applications of CO detection technologies. Semin Perinatol 1994;18:2-10.
61. 61. Vreman HJ, Stevenson DK. Heme oxygenase activity as measured by carbon monoxide production. Anal Biochem 1988;168: 31-8.
62. 62. Coceani F, Kelsey L, Seidlitz E, Marks GS, McLaughlin BE, Vreman HJ, et al. Carbon monoxide formation in the ductus arteriosus in the lamb: implications for the regulation of muscle tone. Br J Pharmacol 1997;120:599-608.
63. 63. Meffert MK, Haley JE, Schuman EM, Schulman H, Madison DV. Inhibition of hippocampal heme oxygenase, nitric oxide synthase, and long-term potentiation by metalloporphyrins. Neuron 1994;13:1225-33.
64. 64. Hamori CJ, Vreman HJ, Rodgers PA, Stevenson DK. Zinc protoporphyrin inhibits CO production in rats. J Pediatr Gastroenterol Nutr 1989;8:110-5.
65. 65. Hamori CJ, Lasic DD, Vreman HJ, Stevenson DK. Targeting zinc protoporphyrin liposomes to the spleen using reticuloendothelial blockade with blank liposomes. Pediatr Res 1993;34:1-5.
66. 66. Rodgers PA, Vreman HJ, Stevenson DK. Heme catabolism in rhesus neonates inhibited by zinc protoporphyrin. Dev Pharmacol Ther 1990;14:216-22.
67. 67. Vallier HA, Rodgers PA, Stevenson DK. Inhibition of heme oxygenase after oral vs intraperitoneal administration of chromium porphyrins. Life Sci 1993;52:L79-84.
68. 68. Bartoletti AL, Stevenson DK, Ostrander CR, Johnson JD. Pulmonary excretion of carbon monoxide in the human infant as an index of bilirubin production. I. Effects of gestational and postnatal age and some common neonatal abnormalities. J Pediatr 1979;94:952-5.
69. 69. Ostrander CR, Cohen RS, Hopper AO, Cowan BE, Stevens GB, Stevenson DK. Paired determinations of blood carboxyhemoglobin concentration and carbon monoxide excretion rate in term and preterm infants. J Lab Clin Med 1982;100:745-55.
70. 70. Mahoney JJ, Vreman HJ, Stevenson DK, Van Kessel AL. Measurement of carboxyhemoglobin and total hemoglobin by five specialized spectrophotometers (CO-oximeters) in comparison with reference methods. Clin Chem 1993;39:1693-700.
71. 71. Uetani Y, Nakamura H, Okamoto O, Yamazaki T, Vreman HJ, Stevenson DK. Carboxyhemoglobin measurements in the diagnosis of ABO hemolytic disease. Acta Paediatr Jpn 1989;31: 171-6.
72. 72. Vreman HJ, Kwong LK, Stevenson DK. Carbon monoxide in blood: an improved microliter blood-sample collection system, with rapid analysis by gas chromatography. Clin Chem 1984;30: 1382-6.
73. 73. Vreman HJ, Stevenson DK, Zwart A. Analysis for carboxyhemoglobin by gas chromatography and multicomponent spectrophotometry compared. Clin Chem 1987;33:694-7.
74. 74. Smith DW, Inguillo D, Martin D, Vreman HJ, Cohen RS, Stevenson DK. Use of noninvasive tests to predict significant jaundice in full-term infants: preliminary studies. Pediatrics 1985;75: 278-80.
75. 75. Vreman HJ, Stevenson DK, Oh W, Fanaroff AA, Wright LL, Lemons JA, et al. Semiportable electrochemical instrument for determining carbon monoxide in breath. Clin Chem 1994;40:1927-33.
76. 76. Vreman HJ, Baxter LM, Stone RT, Stevenson DK. Evaluation of a fully automated end-tidal carbon monoxide instrument for breath analysis. Clin Chem 1996;42:50-6.
77. 77. McCoubrey WK Jr, Huang TJ, Maines MD. Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. Eur J Biochem 1997;247:725-32.
78. 78. Drummond GS, Kappas A. Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxidation. Proc Natl Acad Sci U S A 1981;78:6466-70.
79. 79. Vreman HJ, Stevenson DK. Detection of heme oxygenase activity by measurement of CO. In: Maines MD, Costa LG, Reed DJ, Sassa S, Sipes IG, eds. Current protocols in toxicology. New York: Wiley & Sons, 1999 9.2.1-10.
80. 80. Hastka J, Lasserre JJ, Schwarzbeck A, Reiter A, Hehlmann R. Laboratory tests of iron status: correlation or common sense? [see comments] Clin Chem 1996;42:718-24.
81. 81. Hastka J, Lasserre JJ, Schwarzbeck A, Hehlmann R. Central role of zinc protoporphyrin in staging iron deficiency. Clin Chem 1994;40:768-73.
82. 82. Siegel RM, LaGrone DH. The use of zinc protoporphyrin in screening young children for iron deficiency. Clin Pediatr 1994; 33:473-9.
83. 83. Kazal LA Jr. Failure of hematocrit to detect iron deficiency in infants [see comments]. J Family Pract 1996;42:237-40.
84. 84. Rettmer RL, Carlson, TH, Origenes ML, Jack RM, Labbé RF. Zinc protoporphyrin/heme ratio for diagnosis of preanemic iron deficiency. Pediatrics 1999; 104:e37.
85. 85. Graham EA, Carlson TH, Sodergren KK, Detter JC, Labbe R. Iron deficiency and delayed weaning in Southeast Asian toddlers. West J Med 1997;167:10-4.
86. 86. Walter T. Effect of iron-deficiency anaemia on cognitive skills in infancy and childhood. Baillieres Clin Haematol 1994;7:815-27.
87. 87. Yip R. The interaction of lead and iron. In: Filer LJJ, ed. Dietary iron, birth to two years. New York: Raven Press, 1989:179-81.
88. 88. Romslo I, Haram K, Sagen N, Augensen K. Iron requirement in normal pregnancy as assessed by serum ferritin, serum transferrin saturation and erythrocyte protoporphyrin determinations. Br J Obstet Gynaecol 1983;90:101-7.
89. 89. Schifman RB, Thomasson JE, Evers JM. Red blood cell zinc protoporphyrin testing for iron-deficiency anemia in pregnancy [see comments]. Am J Obstet Gynecol 1987;157:304-7.
90. 90. Stein J. Assessing iron status in pregnancy: relationship between zinc protoporphyrin/heme ratio and volume-corrected serum ferritin [Thesis]. Nursing. Spokane, WA : Gonzaga University, 1999:39.
91. 91. Schifman RB, Rivers SL, Finley PR, Thies C. RBC zinc protoporphyrin to screen blood donors for iron deficiency anemia. JAMA 1982;248:2012-5.
92. 92. Jensen BM, Sandø SH, Grandjean P, Wiggers P, Dalhøj J. Screening with zinc protoporphyrin for iron deficiency in nonanemic female blood donors. Clin Chem 1990;36:846-8.
93. 93. Harthoorn-Lasthuizen EJ, Lindemans J, Langenhuijsen MM. Zinc protoporphyrin as screening test in female blood donors. Clin Chem 1998;44:800-4.
94. 94. Finch C. Regulators of iron balance in humans [see comments]. Blood 1994;84:1697-702.
95. 95. Birgegȧrd G, de Verdier CH, Högman C. A comparison between concentrations of free erythrocyte protoporphyrin and serum ferritin during development of iron deficiency by phlebotomy in polycythaemia vera patients. Scand J Clin Lab Investig 1987;47: 593-7.
96. 96. Hastka J, Lasserre JJ, Schwarzbeck A, Strauch M, Hehlmann R. Zinc protoporphyrin in anemia of chronic disorders. Blood 1993; 81:1200-4.
97. 97. Wong SS, Qutishat AS, Lange J, Gornet TG, Buja LM. Detection of iron-deficiency anemia in hospitalized patients by zinc protoporphyrin. Clin Chim Acta 1996;244:91-101.
98. 98. Pootrakul P, Wattanasaree J, Anuwatanakulchai M, Wasi P. Increased red blood cell protoporphyrin in thalassemia: a result of relative iron deficiency. Am J Clin Pathol 1984;82:289-93.
99. 99. Stockman JA, Weiner LS, Simon GE, Stuart MJ, Oski FA. The measurement of free erythrocyte porphyrin (FEP) as a simple means of distinguishing iron deficiency from beta-thalassemia trait in subjects with microcytosis. J Lab Clin Med 1975;85: 113-9.
100. 100. Graham EA, Felgenhauer J, Detter JC, Labbe RF. Elevated zinc protoporphyrin associated with thalassemia trait and hemoglobin E. J Pediatr 1996;129:105-10.
101. 101. Harthoorn-Lasthuizen EJ, Lindemans J, Langenhuijsen MM. Combined use of erythrocyte zinc protoporphyrin and mean corpuscular volume in differentiation of thalassemia from iron deficiency anemia. Eur J Haematol 1998;60:245-51.
102. 102. Fishbane S, Lynn R. The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis 1995;25:426-32.
103. 103. Braun J, Hammerschmidt M, Schreiber M, Heidler R, Hörl WH. Is zinc protoporphyrin an indicator of iron-deficient erythropoiesis in maintenance haemodialysis patients? Nephrol Dial Transplant 1996;11:492-7.
104. 104. Baldus M, Salopek S, Moller M, Schliessen J, Klocker P, Redding J, et al. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients. Nephrol Dial Transplant 1996;11:486-91.
105. 105. Schwartz S, Stephenson B, Sarkar D, Freyholtz H, Ruth G. Quantitative assay of erythrocyte "free" and zinc-protoporphyrin: clinical and genetic studies. Int J Biochem 1980;12:1053-7.
106. 106. Jacobs JM, Sinclair PR, Sinclair JF, Gorman N, Walton HS, Wood SG, Nichols C. Formation of zinc protoporphyrin in cultured hepatocytes: effects of ferrochelatase inhibition, iron chelation or lead. Toxicology 1998;125:95-105.
107. 107. Nunn AV, Norris P, Hawk JL, Cox TM. Zinc chelatase in human lymphocytes: detection of the enzymatic defect in erythropoietic protoporphyria. Anal Biochem 1988;174:146-50.
108. 108. CDC. Preventing lead poisoning in young children. Atlanta, GA: CDC, 1991.
109. 109. Parsons PJ, Reilly AA, Hussain A. Observational study of erythrocyte protoporphyrin screening test for detecting low lead exposure in children: impact of lowering the blood lead action threshold. Clin Chem 1991;37:216-25.
110. 110. Zwennis WC, Franssen AC, Wijnans MJ. Use of zinc protoporphyrin in screening individuals for exposure to lead. Clin Chem 1990;36:1456-9.
111. 111. Zhang WS, Contag PR, Contag CH, Stevenson DK. Effects of metalloporphyrins on heme oxygenase-1 expression. J Investig Med 1999;46:33A.
112. 112. Mayer SE, Melmon KL, Gilman AG. Introduction: the dynamic of drug absorption, distribution, and elimination. In: Gilman AG, Goodman LS, Gilman A, eds. The pharmacological basis of therapeutics, 6th ed. New York: Macmillan Publishing, 1980: 5-9.
113. 113. Vreman HJ, Hintz SR, Kim CB, Castillo RO, Stevenson DK. Effects of oral administration of tin and zinc protoporphyrin on neonatal and adult-rat tissue heme oxygenase activity. J Pediatr Gastroenterol Nutr 1988;7:902-6.
114. 114. Maines MD, Veltman JC. Phenylhydrazine-mediated induction of haem oxygenase activity in rat liver and kidney and development of hyperbilirubinaemia. Inhibition by zinc-protoporphyrin. Biochem J 1984;217:409-17.
115. 115. Galbraith RA, Kappas A. Pharmacokinetics of tin-mesoporphyrin in man and the effects of tin-chelated porphyrins on hyperexcretion of heme pathway precursors in patients with acute inducible porphyria. Hepatology 1989;9:882-8.
116. 116. Appleton SD, Chretien ML, McLaughlin BE, Vreman HJ, Stevenson DK, Brien JF, et al. Selective inhibition of heme oxygenase, without inhibition of nitric oxide synthase or soluble guanylyl cyclase, by metalloporphyrins at low concentrations. Drug Metab Dispos 1999;27:1214-9.
117. 117. Smith KM. Porphyrins and metalloporphyrins. New York: Elsevier, 1975:889pp.
118. 118. Bailey GG, Needham LL. Simultaneous quantification of erythrocyte zinc protoporphyrin and protoporphyrin IX by liquid chromatography. Clin Chem 1986;32:2137-42.
119. 119. Leonard JJ, Yonetani T, Callis JB. A fluorescence study of hybrid hemoglobins containing free base and zinc protoporphyrin IX. Biochemistry 1974;13:1460-4.
120. 120. Hirsch RE, Lin MJ, Park CM. Interaction of zinc protoporphyrin with intact oxyhemoglobin. Biochemistry 1989;28:1851-5.
121. 121. Gunter EW, Turner WE, Huff DL. Investigation of protoporphyrin IX standard materials used in acid-extraction methods, and a proposed correction for the millimolar absorptivity of protoporphyrin IX. Clin Chem 1989;35:1601-8.
122. 122. Lamola AA, Eisinger J, Blumberg WE, Kometani T, Burnham BF. Quantitative determination of erythrocyte zinc protoporphyrin. J Lab Clin Med 1977;89:881-90.
123. 123. Poh-Fitzpatrick MB, Lamola AA. Direct spectrofluorometry of diluted erythrocytes and plasma: a rapid diagnostic method in primary and secondary porphyrinemias. J Lab Clin Med 1976; 87:362-70.
124. 124. Chisolm JJ, Brown DH. Micromethod for zinc protoporphyrin in erythrocytes: including new data on the absorptivity of zinc protoporphyrin and new observations in neonates and sickle cell disease. Biochem Med 1979;22:214-37.
125. 125. Lamola AA, Eisinger J, Blumberg WE. Erythrocyte protoporphyrin/ heme ratio by hematofluorometry [Letter]. Clin Chem 1980;26: 677-8.
126. 126. Schifman RB, Finley PR. Measurement of near-normal concentrations of erythrocyte protoporphyrin with the hematofluorometer: influence of plasma on "front-surface illumination" assay. Clin Chem 1981;27:153-6.
127. 127. Hastka J, Lasserre JJ, Schwarzbeck A, Strauch M, Hehlmann R. Washing erythrocytes to remove interferents in measurements of zinc protoporphyrin by front-face hematofluorometry. Clin Chem 1992;38:2184-9.
128. 128. Louro MO, Tutor JC. Hematofluorometric determination of erythrocyte zinc protoporphyrin: oxygenation and derivatization of hemoglobin compared. Clin Chem 1994;40:369-72.
129. 129. Labbé RF, Dewanji A, McLaughlin K. Observations on the zinc protoporphyrin/heme ratio in whole blood. Clin Chem 1999;45: 146-8.
130. 130. Rettmer RL, Gunter EW, Labbe RF. Overcoming the limitations of hematofluorometry for assaying zinc protoporphyrin. Ann N Y Acad Sci 1987;514:345-6.